MediTarget

MediTarget is a South Korean biotechnology company specializing in AI-driven drug discovery and development. The company utilizes its proprietary AI platform to identify novel therapeutic targets and optimize small molecule candidates, with a primary focus on oncology, metabolic disorders, and fibrosis. MediTarget's lead programs include inhibitors targeting challenging proteins such as KRAS G12D. By integrating advanced computational modeling with biological validation, the company aims to accelerate the development of precision medicines for high-unmet-need indications. The firm was founded by industry veterans with significant experience in pharmaceutical R&D and has secured substantial venture backing to advance its internal pipeline.